The Claim
Initiation of semaglutide in adults is associated with an $80 per month increase in healthcare expenditures (excluding drug costs) over a period of 13 to 24 months, primarily due to increased inpatient care for circulatory and metabolic conditions.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When adults start taking semaglutide, their healthcare costs (not including the drug itself) rise by $80 per month on average over 13 to 24 months, mainly because they use more hospital services for heart and metabolic issues.
See the scientific wording
Semaglutide initiation is associated with a $80 per month increase in health care expenditures (excluding drug cost) over 13 to 24 months in adults, driven primarily by increased inpatient care for circulatory and metabolic conditions, suggesting no short-term cost savings despite clinical improvements.
When fat tissue shrinks rapidly, the body releases stored fats and chemicals into the blood, forcing the heart and liver to work harder to process them. This overload causes temporary stress on blood vessels and organs, leading to more hospital visits for heart and metabolism problems.
What the research says
1 studyEven though people taking semaglutide lost weight and got healthier, their hospital visits for heart and metabolism problems went up, making their medical bills $80 more per month—just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.